

Brilliant Violet 421™ anti-mouse/human CD11b Antibody

Catalog# / Size	101235 / 125 μ L 101251 / 50 μ g 101236 / 500 μ L
Clone	M1/70
Regulatory Status	RUO
Other Names	α M integrin, Mac-1, Mo1, CR3, Ly-40, C3biR, ITGAM
Isotype	Rat IgG2b, κ
Description	CD11b is a 170 kD glycoprotein also known as α M integrin, Mac-1 α subunit, Mol, CR3, and Ly-40. CD11b is a member of the integrin family, primarily expressed on granulocytes, monocytes/macrophages, dendritic cells, NK cells, and subsets of T and B cells. CD11b non-covalently associates with CD18 (β 2 integrin) to form Mac-1. Mac-1 plays an important role in cell-cell interaction by binding its ligands ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, and fibrinogen.

Product Details

Verified Reactivity	Mouse, Human, Cynomolgus, Rhesus
Reported Reactivity	Chimpanzee, Baboon, Rabbit
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	C57BL/10 splenocytes
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration	μ g sizes: 0.2 mg/mL μ L sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining using the μ g size, the suggested use of this reagent is \leq 0.25 μ g per million cells in 100 μ L volume. For flow cytometric staining using the μ L sizes, the suggested use of this reagent is 5 μ L per million cells in 100 μ L staining volume or 5 μ L per 100 μ L of whole blood. It is recommended that the reagent be titrated for optimal performance for each application. Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd. Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser	Violet Laser (405 nm)
Application Notes	Clone M1/70 has been verified for immunocytochemistry (ICC) and frozen immunohistochemistry

(IHC-F).

Additional reported applications (for relevant formats of this clone) include: immunoprecipitation^{1,4}, *in vitro* blocking^{3,9,12}, depletion^{2,8}, immunofluorescence microscopy^{6,7,10}, immunohistochemistry of acetone-fixed frozen sections^{5,11-13}, and spatial biology (IBEX)^{35,36}. For *in vivo* studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/μg, Azide-Free, 0.2 μm filtered) (Cat. No. 101248).

Application References

(PubMed link indicates BioLegend citation)

1. Springer T, *et al.* 1978. *Eur. J. Immunol.* 8:539. (IP)
2. Ault K and Springer T. 1981. *J. Immunol.* 126:359. (Deplete)
3. Springer TA, *et al.* 1982. *Immunol. Rev.* 68:171. (Block)
4. Ho MK and Springer TA. 1983. *J. Biol. Chem.* 258:2766. (IP)
5. Flotte TJ, *et al.* 1983. *Am. J. Pathol.* 111:112. (IHC)
6. Noel GJ, *et al.* 1990. *J. Clin. Invest.* 85:208. (IF)
7. Allen LA and Aderem A. 1996. *J. Exp. Med.* 184:627 (IF)
8. D'Amico A and Wu L. 2003. *J. Exp. Med.* 198:293. (Deplete)
9. Brickson SJ, *et al.* 2003. *Appl Physiol.* 95:969. (Block)
10. Clatworthy MR and Smith KG. 2004. *J. Exp. Med.* 199:717. (IF)
11. Hata H, *et al.* 2004. *J. Clin. Invest.* 114:582. (IHC)
12. Zhang Y, *et al.* 2002. *J. Immunol.* 168:3088. (IHC)
13. Iwasaki A and Kelsall BL. 2001. *J. Immunol.* 166:4884 (IHC, FC)
14. Tailleux L. 2003. *J. Exp. Med.* 197:121. (Block, FC)
15. Olver S, *et al.* 2006. *Cancer Research* 66:571. (FC)
16. Tan SL, *et al.* 2006. *J. Immunol.* 176:2872. (FC) [PubMed](#)
17. Ponomarev ED, *et al.* 2006. *J. Immunol.* 176:1402. (FC)
18. Dzhagalov I, *et al.* 2007. *Blood* 109:1620. (FC)
19. Fazilleau N, *et al.* 2007. *Nature Immunol.* 8:753.
20. Rasmussen JW, *et al.* 2006. *Infect. Immun.* 74:6590. [PubMed](#)
21. Napimoga MH, *et al.* 2008. *J. Immunol.* 180:609. [PubMed](#)
22. Elqaraz-Carmon V, *et al.* 2008. *J. Lipid. Res.* 49:1894. [PubMed](#)
23. Kim DD, *et al.* 2008. *Blood* 112:1109. [PubMed](#)
24. Guo Y, *et al.* 2008. *Blood* 112:480. [PubMed](#)
25. Norian LA, *et al.* 2009. *Cancer Res.* 69:3086. (FC) [PubMed](#)
26. Baumgartner CK, *et al.* 2010. *J. Immunol.* 184:573. [PubMed](#)
27. Charles N, *et al.* 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
28. Whiteland J, *et al.* 1995. *J. Histochem. Cytochem.* 43:313. (IHC)
29. Weber GF, *et al.* 2014. *J Exp Med.* 211:1243. [PubMed](#)
30. Ashok A, *et al.* 2015. *Toxicol Sci.* 143:64. [PubMed](#)
31. Price PJ, *et al.* 2015. *J Immunol.* 194:1164. [PubMed](#)
32. Doni A, *et al.* 2015. *J Exp Med.* 212:905. [PubMed](#)
33. Ferreira R, *et al.* 2016. *J Infect Dis.* 213: 669 - 673. [PubMed](#)
34. Peterson VM, *et al.* 2017. *Nat. Biotechnol.* 35:936. (PG)
35. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
36. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Kakizaki M, Watanabe R 2017. *Neuropathology.* 10.1111/neup.12386. [PubMed](#)
2. Skucha A, *et al.* 2018. *Nat Commun.* 9:1983. [PubMed](#)
3. Geng X, *et al.* 2018. *Aging (Albany NY).* 10:1415. [PubMed](#)
4. Zukauskas A, *et al.* 2018. *mSphere.* 3:e00303. [PubMed](#)
5. Cong J *et al.* 2018. *Cell metabolism.* 28(2):243-255. [PubMed](#)
6. Li Z *et al.* 2018. *Immunity.* 49(4):640-653. [PubMed](#)
7. Sokol CL *et al.* 2018. *Immunity.* 49(3):449-463. [PubMed](#)
8. Xu D *et al.* 2018. *Cell.* 174(6):1477-1491. [PubMed](#)
9. Sabbagh MF *et al.* 2018. *eLife.* 7 pii: e36187. [PubMed](#)
10. Grzelak A, *et al.* 2018. *Int J Mol Sci.* 19:. [PubMed](#)
11. Laban H, *et al.* 2018. *J Cell Biol.* 217:1503. [PubMed](#)
12. Knox T, *et al.* 2019. *Sci Rep.* 9:6136. [PubMed](#)
13. Yousef H, *et al.* 2018. *Bio Protoc.* 8:22. [PubMed](#)
14. Bryson BD, *et al.* 2019. *Nat Commun.* 10:2329. [PubMed](#)
15. Hou X, *et al.* 2020. *Cell Reports.* 28(1):172-189.e7.. [PubMed](#)
16. Ponzetta A, *et al.* 2020. *Cell.* 178(2):346-360.e24.. [PubMed](#)
17. Rashidi M, *et al.* 2019. *J Immunol.* 203:736. [PubMed](#)
18. Di Mitri D, *et al.* 2019. *Cell Rep.* 28:2156. [PubMed](#)
19. Toshiro Hirai *et al.* 2019. *Immunity.* 50(5):1249-1261. [PubMed](#)
20. Liu J, *et al.* 2019. *Immunity.* 50:600. [PubMed](#)
21. Li Q, *et al.* 2019. *Neuron.* 101:207. [PubMed](#)
22. Cho C *et al.* 2017. *Neuron.* 95(5):1056-1073. [PubMed](#)
23. Kim I *et al.* 2015. *Brain and behavior.* 5(12):e00403. [PubMed](#)
24. Ma C, *et al.* 2018. *Science.* 360:eaan5931. [PubMed](#)
25. Yousef H, *et al.* 2019. *Nat Med.* 25:988. [PubMed](#)
26. Currier MA, *et al.* 2017. *Oncotarget.* 8:17412. [PubMed](#)
27. Buzzelli JN, *et al.* 2019. *Am J Physiol Gastrointest Liver Physiol.* 316:G251. [PubMed](#)
28. Qi F, *et al.* 2019. *Front Microbiol.* 2.140277778. [PubMed](#)
29. Liakopoulos V, *et al.* 2018. *Sci Rep.* 8:13964. [PubMed](#)
30. Kodama L, *et al.* 2020. *Nat Neurosci.* 1.074305556. [PubMed](#)
31. Krivtsov AV, *et al.* 2020. *Cancer Cell.* 36(6):660-673.e11.. [PubMed](#)
32. O'Connor T, *et al.* 2020. *Cancer Cell.* 36(3):250-267. [PubMed](#)
33. Ilyukh PA, *et al.* 2020. *Cell Host & Microbe.* 27(6):976-991. [PubMed](#)

34. Mohamed E, *et al.* 2020. *Immunity*. 52(4):668-682.e7.. [PubMed](#)
35. Liu X, *et al.* 2013. *Diabetes*. 62:4228. [PubMed](#)
36. Weber G, *et al.* 2014. *J Exp Med*. 211:1243. [PubMed](#)
37. Price P, *et al.* 2015. *J Immunol*. 194:1164. [PubMed](#)
38. Doni A, *et al.* 2015. *J Exp Med*. 212:905. [PubMed](#)
39. Motozono C, *et al.* 2015. *J Biol Chem*. 290: 18924 - 18933. [PubMed](#)
40. Richardson ET, *et al.* 2015. *PLoS One*. 10: 1371. [PubMed](#)
41. Mairhofer D, *et al.* 2015. *J Invest Dermatol*. 135: 2785-93. [PubMed](#)
42. Ioannidis L, *et al.* 2016. *J Immunol*. 196: 1227 - 1238. [PubMed](#)
43. Däbritz J, *et al.* 2016. *Sci Rep*. 6:20584. [PubMed](#)
44. Bennett M, *et al.* 2016. *Proc Natl Acad Sci U S A*. 113: 1738 - 1746. [PubMed](#)
45. Damgaard RB *et al.* 2016. *Cell*. 166(5):1215-1230 . [PubMed](#)
46. Chai Y, *et al.* 2016. *PLoS One*. 11: 0162853. [PubMed](#)
47. Moderzynski K, *et al.* 2016. *PLoS Negl Trop Dis*. . [PubMed](#)
48. Reinert L, *et al.* 2016. *Nat Commun*. 7:13348. [PubMed](#)
49. Yin Z, *et al.* 2017. *Neurobiol Aging*. 10.1016/j.neurobiolaging.2017.03.021. [PubMed](#)
50. Harvey RE *et al.* 2017. *Endocrinology*. 158(7):2179-2189 . [PubMed](#)
51. Chen MB, *et al.* 2020. *Cell Rep*. 30:4418. [PubMed](#)
52. Xu G, *et al.* 2020. *Cell Rep*. 32:108170. [PubMed](#)
53. Pribyl M, *et al.* 2020. *Mol Oncol*. 2.252083333. [PubMed](#)
54. Nakayama Y, *et al.* 2020. *Proc Natl Acad Sci U S A*. 117:14365. [PubMed](#)
55. Miller CM, *et al.* 2020. *J Virol*. 94:00:00. [PubMed](#)
56. Klemm F, *et al.* 2020. *Cell*. 181(7):1643-1660.e17. [PubMed](#)
57. Tummers B, *et al.* 2020. *Immunity*. 52(6):994-1006.e8. [PubMed](#)
58. Acharya N, *et al.* 2020. *Immunity*. 53(3):658-671.e6. [PubMed](#)
59. Perner C, *et al.* 2020. *Immunity*. 53(5):1063-1077.e7. [PubMed](#)
60. Singh S, *et al.* 2021. *Cell Host Microbe*. 29(3):347-361.e12. [PubMed](#)
61. Bae S, *et al.* 2021. *Cell Reports*. 35(11):109264. [PubMed](#)

RRID [AB_10897942](#) (BioLegend Cat. No. 101235)
[AB_2562904](#) (BioLegend Cat. No. 101251)
[AB_11203704](#) (BioLegend Cat. No. 101236)

Antigen Details

Structure	Integrin family, associates with integrin β_2 (CD18), 170 kD
Distribution	Granulocytes, monocytes/macrophages, dendritic cells, NK cells, subsets of T and B cells
Function	Adhesion, chemotaxis
Ligand/Receptor	ICAM-1 (CD54), ICAM-2 (CD102), ICAM-4 (CD242), iC3b, fibrinogen
Cell Type	B cells, Dendritic cells, Granulocytes, Macrophages, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area	Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family	Adhesion Molecules, CD Molecules
Antigen References	<ol style="list-style-type: none"> 1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press. 2. Springer TA. 1994. <i>Cell</i> 76:301. 3. Coxon A, <i>et al.</i> 1996. <i>Immunity</i> 5:653.
Gene ID	16409 3684

Related Protocols


[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats


APC anti-mouse/human CD11b, Biotin anti-mouse/human CD11b, FITC anti-mouse/human CD11b, PE anti-mouse/human CD11b, PE/Cyanine5 anti-mouse/human CD11b, Purified anti-mouse/human CD11b, PE/Cyanine7 anti-mouse/human CD11b, Alexa Fluor® 488 anti-mouse/human CD11b, Alexa Fluor® 647 anti-mouse/human CD11b, Alexa Fluor® 700 anti-mouse/human CD11b, Pacific

Blue™ anti-mouse/human CD11b, APC/Cyanine7 anti-mouse/human CD11b, PerCP/Cyanine5.5 anti-mouse/human CD11b, PerCP anti-mouse/human CD11b, Brilliant Violet 421™ anti-mouse/human CD11b, Brilliant Violet 570™ anti-mouse/human CD11b, Brilliant Violet 605™ anti-mouse/human CD11b, Brilliant Violet 650™ anti-mouse/human CD11b, Brilliant Violet 711™ anti-mouse/human CD11b, Brilliant Violet 785™ anti-mouse/human CD11b, Brilliant Violet 510™ anti-mouse/human CD11b, Ultra-LEAF™ Purified anti-mouse/human CD11b, Purified anti-mouse/human CD11b (Maxpar® Ready), Alexa Fluor® 594 anti-mouse/human CD11b, PE/Dazzle™ 594 anti-mouse/human CD11b, APC/Fire™ 750 anti-mouse/human CD11b, TotalSeq™-A0014 anti-mouse/human CD11b, Brilliant Violet 750™ anti-mouse/human CD11b, TotalSeq™-B0014 anti-mouse/human CD11b, TotalSeq™-C0014 anti-mouse/human CD11b, Spark NIR™ 685 anti-mouse/human CD11b, PE/Fire™ 640 anti-mouse/human CD11b, Spark YG™ 593 anti-mouse/human CD11b, Spark YG™ 570 anti-mouse/human CD11b, PE/Fire™ 810 anti-mouse/human CD11b, APC/Fire™ 810 anti-mouse/human CD11b Antibody, Spark Blue™ 550 anti-mouse/human CD11b, Spark UV™ 387 anti-mouse/human CD11b

Product Data



BL/6 mouse lymph nodes, fixed O/N in PLP, blocked with 10% rat serum, stained with CD11b-BV421™ (red), B220-Alexa Fluor® 647 (blue), CD14-FITC (green) in 1% BSA and 0.1% Tween-20 in PBS. Images were acquired with an automated widefield microscope (Nikon Eclipse Ti) and a CCD camera (QImaging Retiga 2000R). Emitted light was collected through 440/40, 525/50, and 700/75 nm bandpass filters. Images provided by Ann Haberman and Christine Podolski, Yale University.



C57BL/6 mouse bone marrow cells were stained with CD11b (clone M1/70) Brilliant Violet 421™ (filled histogram) or rat IgG2b, κ Brilliant Violet 421™ isotype control (open histogram). Data shown was gated on myeloid cell population.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587